FDA approves Genentech's Enspryng as first at-home TED injection

Genentech's Enspryng (satralizumab-mwge), a subcutaneous treatment for thyroid eye disease (TED), has received FDA approval as the first at-home injection option. The approval follows positive phase 3 trial data showing clinically meaningful improvements in TED symptoms with a favourable safety profile.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.